This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Magnetic Resonance Spectroscopic Imaging (MRS) and Tumor Perfusion of Human Glioblastoma Treated With Concurrent Radiation Therapy and Temozolomide

This study has been completed.
Cross Cancer Institute
Information provided by (Responsible Party):
AHS Cancer Control Alberta Identifier:
First received: November 4, 2005
Last updated: February 23, 2016
Last verified: October 2011
The purpose of this study is to learn whether 3 tesla (3T) MRI functional imaging will map a tumor more accurately allowing a more targeted delivery of radiation. The investigators hope to learn whether tomotherapy will be able to deliver higher radiation doses safely to the tumor while sparing the surrounding normal tissue.

Condition Intervention Phase
Glioblastoma Glioma Procedure: Functional MRI imaging and tomotherapy Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Multimodality Functional Imaging (MRS and Tumor Perfusion) Predicts Tumor Migration, Invasiveness, and Patterns of Failure of Human Glioblastoma Treated With Concurrent Radiation Therapy and Temozolomide

Resource links provided by NLM:

Further study details as provided by AHS Cancer Control Alberta:

Primary Outcome Measures:
  • determine tumor response and pattern of failure using functional MRI imaging [ Time Frame: Study completion ]
  • time to disease progression [ Time Frame: Study completion ]

Secondary Outcome Measures:
  • distinguish residual tumor from treatment-related necrosis [ Time Frame: study completion ]
  • survival
  • acute late toxicity of tomotherapy and hypofractionation

Enrollment: 26
Study Start Date: March 2005
Study Completion Date: April 2011
Primary Completion Date: March 2011 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed glioblastoma multiforme
  • Ages 18-65
  • Karnofsky Performance Scale (KPS) equal to or less than 70
  • Minimal neurological deficit
  • Eligible for concurrent temozolomide chemotherapy

Exclusion Criteria:

  • Prior radiation therapy to hand or neck area, chemotherapy, or radiosensitizer
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00250211

Canada, Alberta
Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2
Sponsors and Collaborators
AHS Cancer Control Alberta
Cross Cancer Institute
Principal Investigator: Bassam Abdulkarim, MD AHS Cancer Control Alberta
  More Information

Responsible Party: AHS Cancer Control Alberta Identifier: NCT00250211     History of Changes
Other Study ID Numbers: CNS-09-0027 / ethics 21780
Study First Received: November 4, 2005
Last Updated: February 23, 2016

Keywords provided by AHS Cancer Control Alberta:
magnetic resonance imaging, functional
radiation therapy
functional imaging
concurrent chemoradiation

Additional relevant MeSH terms:
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents processed this record on June 23, 2017